Salmon calcitonin in the therapy of corticoid-induced osteoporosis

Eur J Clin Pharmacol. 1987;33(1):35-9. doi: 10.1007/BF00610377.


There is uncertainty about the best treatment for steroid-induced osteoporosis. Thirty-six patients with steroid-dependent, chronic obstructive lung disease and associated steroid osteoporosis have been studied, of whom 18 were treated with salmon calcitonin and the other 18 served as controls. Treatment lasted for 6 months and consisted of 100 I.U.s.c. every other day. In the controls there were significant decrements of 1.4% and 3.5%, respectively, in cortical and cortical and trabecular bone mineral content, whereas in subjects on calcitonin there were increments of 2.6% and 2.7%, respectively. Additional evidence of positive effect of calcitonin was derived from the reduced incidence of new fractures occurring during the observation period. A significant reduction in back pain was a further consequence of the hormone therapy.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adrenal Cortex Hormones / adverse effects*
  • Adult
  • Aged
  • Bone and Bones / metabolism
  • Calcitonin / therapeutic use*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Lung Diseases, Obstructive / drug therapy
  • Male
  • Middle Aged
  • Minerals / metabolism
  • Osteoporosis / chemically induced*
  • Osteoporosis / drug therapy
  • Osteoporosis / metabolism
  • Random Allocation


  • Adrenal Cortex Hormones
  • Minerals
  • salmon calcitonin
  • Calcitonin